Statistics for 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

Total visits

views
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer 373

Total visits per month

views
May 2024 0
June 2024 0
July 2024 0
August 2024 0
September 2024 0
October 2024 0
November 2024 0

File Visits

views
Borghaei_2018_24-month.pdf 472

Top country views

views
United States 222
China 60
Germany 14
Sweden 6
Ukraine 6
Canada 4
Russia 4
United Kingdom 2
Italy 2
South Korea 2
Bulgaria 1
Lithuania 1
Malaysia 1
Philippines 1

Top city views

views
Wilmington 58
Fairfield 31
Beijing 21
Guangzhou 14
Houston 13
Washington 13
Cambridge 11
Kiez 9
Ann Arbor 8
Jacksonville 7
Kiev 6
White Plains 6
Nanjing 4
Stockholm 4
Chapel Hill 3
Lake Mary 3
Maanshan 3
Brooklyn 2
Frankfurt Am Main 2
Gunzenhausen 2
Indianapolis 2
North Little Rock 2
Overland Park 2
Rome 2
Ryazan 2
San Francisco 2
Santa Clara 2
Seoul 2
Shanghai 2
Toronto 2
Baltimore 1
Changsha 1
Chaoyang 1
Dearborn 1
Gothenburg 1
Hangzhou 1
Klaipeda 1
Kyoto 1
London 1
Mckinney 1
Moscow 1
Motala 1
Mountain View 1
Newport 1
Norristown 1
Norwalk 1
Nürnberg 1
Ottawa 1
Pasig 1
Philadelphia 1
Quincy 1
Reading 1
Saint Petersburg 1
Scottsdale 1
Seattle 1
Seremban 1
Sofia 1
Torrance 1
Toyota 1
Wenzhou 1
Zhongyuan 1